Identification and Characterization of the Sulfate Precipitate in GI147211C IV Formulation

Abstract

GI147211, a water soluble analog of camptothecin, is currently being investigated for the treatment of cancer as a topoisomerase I inhibitor. Precipitate was observed in some samples of a stability lot of the IV clinical formulation after being stored at 5°Cfor one month. The precipitate was identified as the sulfate salt of GI147211 by various techniques including Environmental Scanning Electron Microscope / Energy Dispersive X-ray (ESEM/EDX) and Ion Chromatography (IC). The cause of the precipitation was proven to be from the presence of residual sulfate ions in ammonium sulfate treated glass vials that were suspected to be improperly washed. The solubility product (K_sp) of the sulfate salt was determined in 5% dextrose solution adjusted to pH 3.5 at 5°C to mimic the clinical formulation and refrigerated storage conditions. The K_sp was also determined at 15 and 33°C to determine the temperature effect on the constant. The stoichiometry of the sulfate salt was determined by solubility experiments using HPLC and IC to be 2:1 (base/salt). Based on the stoichiometry, the K_sp was calculated to be 3.04 x 10^–12, 9.27 x 1O^–12 and 9.96 x 10^–11 M³ at 5°C, 15°Cand33°C, respectively. Using the K_sp values, the sulfate threshold in GI147211 Injection when GI147211 sulfate precipitates was determined to be 1.3, 3.8 and 41 ppm at 5, 15 and 33°C, respectively. Further experiments demonstrated that using the proper cleaning techniques the sulfate level in the treated vials was reduced to < 1.3 ppm. The washing cycles for the vials used for clinical supplies were thereafter modified so that the sulfate precipitate would no longer be an issue.